INC. (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On February 11, 2020, Sterling Bancorp, Inc. (the “Company”) reported that its Board of Directors approved a cash dividend of $0.01 per common share, payable on February 28, 2020 to shareholders of record as of February 21, 2020. The Company issued a press release attached to this Form 8-K as Exhibit No. 99 and incorporated herein by reference.
The information contained in this item, including that which is incorporated by reference, is being furnished to the Securities and Exchange Commission. Such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information shall not be deemed incorporated by reference into any registration statement or other document filed to the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is furnished herewith:
| Press Release of Sterling Bancorp, Inc. dated February 11, 2020 |
Sterling Bancorp, Inc. Exhibit
EX-99 2 tm207351d1_ex99.htm EXHIBIT 99 Exhibit 99 Sterling Bancorp Declares Cash Dividend on Common Stock Southfield,…
To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
